It is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well. Clofibrate is a ligand agonist for PPARα (peroxisome proliferator-activated receptor α), or an inducer of cytochromes P450s CYP4A1 and CYP4A3.
S Oikawa; H Midorikawa.[Clofibrate treatment of hyperlipoproteinemia]. Nippon rinsho. Japanese journal of clinical medicine.1994, 52 (12), 3285-3291.
W Reuter; A Seifert. [The treatment of essential hyperlipidemia with clofibrate]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete. 1969, 24 (1), Suppl-Supp7.
Mentions de danger (UE): H302-H315-H318-H335
Harmful if swallowed. Causes skin irritation. Causes serious eye damage. May cause respiratory irritation.
Mentions de prudence: P261-P280a-P305+P351+P338-P304+P340-P405-P501a
Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves and eye/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.